Article: Teva Announces Approval of Generic Accupril(R) Tablets.

JERUSALEM, Israel -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that, following the expiration of pediatric exclusivity for U.S. Patent No. 4,743,450, the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Pfizer's hypertension treatment Accupril[R] (Quinapril Hydrochloride) Tablets, 5 mg, 10 mg, 20 mg and 40 mg. Shipment of this product will commence shortly.

Total annual sales of Quinapril HCl Tablets in the U.S., including brand and generic sales, were approximately $150 million for the twelve months ended June 30, 2007, based on IMS ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!